No Data
ASCLETIS-B (01672.HK) repurchased 0.016 million shares on December 12.
Gelonghui reported on December 12 that ASCLETIS-B (01672.HK) announced the repurchase of 0.016 million shares on December 12, 2024, at a cost of 0.0315 million Hong Kong dollars, with a repurchase price of 1.97 Hong Kong dollars per share.
ASCLETIS-B (01672) spent 0.1026 million Hong Kong dollars to repurchase 0.054 million shares on December 11.
ASCLETIS-B (01672) announced that on December 11, 2024, the company will invest 10.26...
ASCLETIS-B (01672.HK) spent 0.374 million Hong Kong dollars to repurchase 0.201 million shares on December 10.
On December 10, the Hong Kong Stock Exchange reported that ASCLETIS-B (01672.HK) announced that it spent 0.374 million HKD to buy back 0.201 million shares.
On December 9, 2023, Singlory Pharmaceutical-B (01672) invested HKD 0.376 million to repurchase 0.207 million shares.
Gere Pharmaceuticals-B (01672) announced that on December 9, 2024, the company invested 0.376 million Hong Kong dollars...
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
No Data
